Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for IDE397 (MAT2A) + Trodelvy in MTAP-Deletion Urothelial Cancer. The expected timing is based on the latest available company guidance and may change.
4/10/25- Initiated Ph1/2 study expansion with clinical program update in 2025. 11/04/25:- Reported positive Ph1/2 UC data, selected go-forward dose, FPI in NSCLC, next update planned H1 2026. 02/17/26:- Updated data at a 2026 medical conference. 03/09/26:- Deprioritized Trodelvy combo; concluding enrollment in ongoing Ph1/2 Gilead trials. 05/05/26:- Reiterated March decision to deprioritize IDE397 plus Trodelvy combo and conclude ongoing Ph1/2 enrollment. 08/04/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.